Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00788099 · ClinicalTrials.gov registry record · Phase 1

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

A Phase 1 study of Advanced Solid Tumors and Lymphomas, sponsored by PharmaMar.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
2
Study locations

NCT00788099: Completed Phase 1 study of Advanced Solid Tumors and Lymphomas, sponsored by PharmaMar.

NCT00788099 is a Phase 1 study of Advanced Solid Tumors and Lymphomas that has completed, run by PharmaMar. The registered enrollment target is 45 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00788099, a Phase 1 study of Advanced Solid Tumors and Lymphomas, has completed, sponsored by PharmaMar.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.

Conditions Studied

Advanced Solid Tumors Lymphomas

Interventions

  • DRUG Plitidepsin and Sorafenib
  • DRUG Gemcitabine and Plitidepsin

Study Locations (2)

New Jersey

  • The Cancer Institute of New Jersey (CINJ) - New Brunswick

Other

  • Institut Gustave Roussy - Villejuif

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2008-12
Est. Completion 2011-06
Phase Phase 1
PharmaMar

32 total trials

What the finished NCT00788099 record still lists

NCT00788099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (77% lower).

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Plitidepsin and Sorafenib is the first listed.

NCT00788099 reports a single indexed study location in New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT00788099 about?

NCT00788099 is a clinical study titled "Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas". Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib...

What is the current status of trial NCT00788099?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-12. Estimated completion is 2011-06.

What conditions does trial NCT00788099 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Lymphomas.

What interventions are being tested in trial NCT00788099?

The interventions under investigation include: Plitidepsin and Sorafenib (DRUG), Gemcitabine and Plitidepsin (DRUG).

Who is sponsoring clinical trial NCT00788099?

This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00788099 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00788099's enrollment target sits among peer trials

45 105th of 144 higher than 40 of 144 other Advanced Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00788099, the US trial registry maintained by the National Library of Medicine. NCT00788099 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.